CD19 and myasthenia gravis: A Phase 1 clinical trial is currently ongoing to evaluate CAAR T cell therapy as a treatment for Muscle-specific tyrosine kinase (MuSK) Myasthenia Gravis (NCT05451212), though the other currently ongoing clinical trials for CAR T cells in autoimmune disease are focused on anti-CD19 and anti-BCMA CAR T cells.